Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

Schizophrenia Research
Rajiv TandonMatcheri S Keshavan

Abstract

The introduction of second-generation antipsychotics and cognitive therapies for schizophrenia over the past two decades generated considerable optimism about possibilities for recovery. To what extent have these developments resulted in better outcomes for affected individuals? What is the current state of our science and how might we address the many unmet needs in the prevention and treatment of schizophrenia? We trace the evolution of various treatments for schizophrenia and summarize current knowledge about available pharmacological and psychosocial treatments. We consider the widely prevalent efficacy-effectiveness gap in the application of available treatments and note the significant variability in individual treatment response and outcome. We outline an individualized treatment approach which emphasizes careful monitoring and collaborative decision-making in the context of ongoing benefit-risk assessment. We note that the evolution of both pharmacological and psychosocial treatments thus far has been based principally on serendipity and intuition. In view of our improved understanding of the etiology and pathophysiology of schizophrenia, there is an opportunity to develop prevention strategies and treatments based on t...Continue Reading

References

Sep 1, 1992·The American Journal of Psychiatry·A D LoebelS R Szymanski
Feb 11, 1992·Psychiatry Research·C M MazureM B Bowers
Jun 1, 1991·The American Journal of Psychiatry·O M Wolkowitz, D Pickar
Jan 1, 1991·Schizophrenia Bulletin·R J Wyatt
Jan 1, 1988·Schizophrenia Research·R J WyattD G Kirch
May 1, 1988·The American Journal of Psychiatry·W T CarpenterA M Wagman
Sep 1, 1972·The British Journal of Psychiatry : the Journal of Mental Science·G W BrownJ K Wing
Jan 1, 1980·Schizophrenia Bulletin·J M DavisC Chan
Aug 1, 1995·Archives of General Psychiatry·W R McFarlaneJ Toran
Mar 1, 1995·Archives of General Psychiatry·R J Baldessarini, A C Viguera
May 1, 1993·Archives of General Psychiatry·J LiebermanM Borenstein
Feb 1, 1993·The Journal of Nervous and Mental Disease·A F LehmanC P Myers
Mar 1, 1996·The American Journal of Psychiatry·M F Green
Apr 1, 1997·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R M Bilder
Apr 1, 1997·Pharmacology, Biochemistry, and Behavior·A M Mortimer
Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt
Oct 30, 1998·Journal of Psychiatric Research·J R DeQuardo, R Tandon
Jan 1, 1995·Journal of Mental Health Administration·G R BondD M Fekete
Feb 7, 2001·The American Journal of Psychiatry·J BustilloS Keith
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, R S Keefe
Apr 11, 2001·Schizophrenia Research·R A GouldD Goff
May 19, 2001·BMJ : British Medical Journal·D M CoulterI R Edwards
May 31, 2001·The Journal of Nervous and Mental Disease·N A Rector, A T Beck
Aug 2, 2001·Schizophrenia Research·R J Wyatt, I Henter
Oct 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C E AdamsA S David
Nov 3, 2001·The American Journal of Psychiatry·A H Glassman, J T Bigger
Feb 13, 2002·Archives of General Psychiatry·Anthony F LehmanKaren McDonnell
Apr 3, 2002·The Journal of Clinical Psychiatry·Stefan LeuchtWerner Kissling

❮ Previous
Next ❯

Citations

Aug 17, 2011·Pharmacogenomics·Tim MoonsGeert Dom
Jul 6, 2014·BioMed Research International·Nevena DivacNatasa Cerovac
Jun 7, 2014·Pharmacological Reports : PR·Pascual Ángel Gargiulo, Adriana Inés Landa De Gargiulo
Jan 2, 2014·Schizophrenia Research and Treatment·Jeanette M Jerrell, Stephanie Hrisko
Jun 20, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Peggy BoschAnton Coenen
Sep 14, 2014·Asian Journal of Psychiatry·Dawn BruijnzeelRajiv Tandon
Mar 2, 2012·Women's Health·Mary V Seeman
Nov 10, 2012·BMC Psychiatry·Piotr ŚwitajSomnath Chatterji
May 10, 2011·Neuropsychiatric Disease and Treatment·Meghan E McIlwainBruce R Russell
Apr 28, 2011·Pharmacogenomics·Panos Bitsios, Panos Roussos
Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Dec 29, 2011·Epidemiology and Psychiatric Sciences·H NasrallahM Keshavan
Oct 16, 2015·Scandinavian Journal of Occupational Therapy·S T B BjørkedalT Møller
Oct 27, 2011·International Review of Psychiatry·Wolfgang GaebelThomas Wobrock
Feb 28, 2016·Psychiatry Research·Eluana GomesRui Corredeira
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Oct 24, 2015·Trends in Cognitive Sciences·Tyrone D Cannon
Jan 26, 2016·Archives of Psychiatric Nursing·Marc De HertDan Cohen
Feb 6, 2013·Asian Journal of Psychiatry·Rajiv Tandon
Aug 30, 2012·The Psychiatric Clinics of North America·Rajiv Tandon
Oct 12, 2012·Asian Journal of Psychiatry·Ashley ClarkRajiv Tandon
Oct 12, 2012·Asian Journal of Psychiatry·Rajiv Tandon
Nov 8, 2011·Journal of Psychiatric Research·John P LyneBrian O'Donoghue
Jan 6, 2016·Parasites & Vectors·Jaroslav Flegr, Zdeněk Hodný
May 3, 2011·Schizophrenia Research·Shitij Kapur
Apr 2, 2011·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Apr 5, 2011·Schizophrenia Research·William T Carpenter
Dec 18, 2015·BBA Clinical·Marieke J H BegemannIris E C Sommer
Jun 17, 2014·CNS Neuroscience & Therapeutics·Jean-Michel AzorinMarc Adida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here